Leveljump Health Stock Price, News & Analysis

LevelJump Healthcare Corp. reported strong Q1 2025 financial results with revenues of $4.58 million, representing a 12.8% increase from Q1 2024's $4.06 million. The company achieved a net profit of $200,566 and EBITDA of $898,017. Its subsidiary, Canadian Teleradiology Services, contributed $1.03 million in EBITDA. The company expects the revocation of a cease trade order after becoming current with disclosure obligations. Additionally, LevelJump has agreed to acquire two diagnostic imaging clinics in Calgary, with the deal expected to close in July 2025. The company anticipates trading reinstatement on the TSX Venture Exchange once the cease trade order is lifted.

LevelJump Healthcare Corp. reported strong financial results for 2024, with revenues reaching $17.7 million, representing a 41% increase from $12.6 million in 2023. The company's Q4 2024 revenue was $4.8 million with a net profit of $1.95 million, while the full-year net profit stood at $1.2 million. Canadian Teleradiology Services, their wholly-owned subsidiary, achieved EBITDA of $3.35 million. The company reported full-year EBITDA of $1.54 million, with Q4 EBITDA at $395,936. LevelJump is currently interpreting imaging scans for approximately 200,000 patients annually. Post year-end, the company announced plans to acquire two diagnostic imaging outpatient clinics in Calgary, Alberta, with the transaction expected to close by July 2025.

LevelJump Healthcare's subsidiary CTS has signed a definitive agreement to acquire two diagnostic imaging clinics in Calgary, Alberta for $1.92 million in cash. The IHFs provide x-ray, ultrasound, and mammography services, generating combined revenue of $2.2 million and EBITDA of $500,000. The acquisition, expected to close in July 2025, is subject to regulatory approval, due diligence, and securing institutional financing. Additionally, the company announced a delay in filing its 2024 year-end reporting documents, now expected within 7-10 days, after which it will seek to lift the current cease trade order and reinstate trading on TSX Venture Exchange.

LevelJump Healthcare has announced a delay in filing its annual audited financial statements for the fiscal year ending December 31, 2024. The company expects a cease trade order from the Ontario Securities Commission due to missing the April 30, 2025 deadline.

The delay stems from the company's significant growth, with gross revenues increasing over 30% between September 2023 and September 2024, primarily due to Alberta acquisitions. To address these challenges, LevelJump has:

• Implemented new accounting software and controls
• Engaged Ernst & Young as external consultants
• Made improvements following OSC's disclosure review

LevelJump expects to file the required documents within 30 days after the deadline and plans to apply for reinstating its TSX Venture Exchange listing afterward.

LevelJump Healthcare Corp. (TSXV: JUMP) announces the Ontario Securities Commission has revoked the failure-to-file cease trade order (FFCTO) issued on May 7, 2024. The FFCTO was initially imposed due to the company's failure to file required annual financial statements and documentation for 2023.

Following a continuous disclosure review, LevelJump has:

• Refiled MD&A for year-end 2023
• Refiled interim financials for Q1 and Q2 2024
• Filed CEO/CFO certifications
• Refiled Annual Information Form
• Filed Q3 2024 financials

The company has committed to holding a shareholder meeting within three months of the FFCTO revocation. LevelJump's core business remains focused on providing telehealth solutions and in-person radiology services through its diagnostic centres. The company will now seek trading resumption approval from the TSX Venture Exchange.

LevelJump Healthcare reported its Q3 2024 financial results, showing significant improvement. Q3 revenues reached $4.45 million, up 57% year-over-year, with gross profit of $880,194. The quarterly net loss narrowed to $(18,960) from $(1,668,916) in 2023, while EBITDA was $704,834. For the first nine months of 2024, revenues totaled $12.9 million with EBITDA of $1,365,030. The company opened a new location at Yonge Sheppard in September and is currently working to resolve a Cease Trade Order with the OSC to reinstate trading on TSX Venture Exchange.

LevelJump Healthcare Corp. (TSXV: JUMP) has announced the opening of a new medical diagnostic imaging centre in Toronto, Ontario, through its subsidiary Canadian Teleradiology Services, Inc. (CTS). The Yonge Sheppard X-ray and Ultrasound (YSXU) clinic is located in North York and offers extended hours of operation. The 3,000 square foot facility features state-of-the-art equipment, including a new Samsung X-ray machine for faster scan times.

CEO Mitch Geisler emphasized the centre's role in reducing diagnostic imaging wait times in a densely populated area of Toronto. The company also plans to offer additional services through its upcoming Telehospital portal. Additionally, LevelJump has filed an application to revoke a failure to file cease trade order (FFCTO) issued by the Ontario Securities Commission on May 7, 2024, and intends to apply for reinstatement of trading on the TSX Venture Exchange once the FFCTO is revoked.

LevelJump Healthcare Corp (TSXV: JUMP) reported its Q2 2024 financial results, showing significant growth. Key highlights include:

- Canadian Teleradiology Services (CTS) revenues reached $4.4 million, a 42% year-over-year increase.

- Consolidated net income was $179,316 for Q2, with a year-to-date net loss of $(322,039).

- Q2 EBITDA was $655,484, with year-to-date EBITDA of $757,344.

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues, with expectations to grow to over $20 million as the Yonge Sheppard location opens. Gross margins are projected to reach 20% or more.

LevelJump Healthcare Corp. (TSXV: JUMP) has released its Q1 2024 financial results, highlighting strong revenue growth. Key points include:

- Canadian Teleradiology Services (CTS) revenues reached $4.1 million, a 46% year-over-year increase
- Consolidated net loss of $(501,480)
- Consolidated EBITDA of $97,742

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues. With the opening of the Yonge Sheppard location, LevelJump anticipates revenues to grow to over $20 million annually, with consistently positive EBITDA. The company uses non-IFRS financial measures like adjusted EBITDA to evaluate operating performance and liquidity.